Sernova Says FDA Grants Orphan Drug Designation For Autologous Islet Transplantationrttnews·Jun 17 at 12:19 PMSEOVF+1.39%
Keenova Reports First Quarter 2026 Financial Results | MNK Stock NewsStockTitan·May 12 at 02:30 AMSEOVF+1.39%ITRM0.00%
Keenova Launches New Consumer Campaign for Dupuytren's Contracture: Don't Be a Viking | MNK Stock NewsStockTitan·May 4 at 03:30 AMNBRVF0.00%ITRM0.00%
Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at Digestive Disease Week | MNK Stock NewsStockTitan·May 1 at 03:30 AMITRM0.00%NBRVF0.00%
Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders | SEOVF Stock NewsStockTitan·Apr 9 at 03:00 AMIXJ+0.33%VHT+0.10%
06:30 ETKeenova Announces Unaudited Fourth Quarter 2025 Financial Resultsprnewswire·Mar 31 at 10:30 AMLABU-1.91%BBH+0.39%
Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at the SHM Converge | MNK Stock NewsStockTitan·Mar 27 at 03:30 AMRNVA0.00%SEOVF+1.39%
Sernova Raises $2.1 Million in Private Placement to Advance Diabetes ProgramTip Ranks·Mar 24 at 04:40 PMVHT+0.10%SVA0.00%
Valneva shares are trading lower after the company announced with Pfizer topline results from the Phase 3 VALOR "Vaccine Against Lyme for Outdoor Recreationists" clinical trial. The vaccine candidate PF-07307405 demonstrated efficacy of more than 70% in preventing Lyme disease in individuals aged five years and above.benzinga_article·Mar 23 at 02:56 PMIBBQ-0.11%XBI-0.60%
